Stock Scorecard

Stock Summary for PDS Biotechnology Corporation (PDSB) - $0.96 as of 11/13/2025 2:58:23 PM EST

Total Score

10 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PDSB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PDSB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PDSB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PDSB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PDSB (22 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PDSB

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update 11/13/2025 12:30:00 PM
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering 11/11/2025 8:31:00 PM
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 - PDS Biotechnology ( NASDAQ:PDSB ) 11/10/2025 1:30:00 PM
New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer ( SITC ) Annual Meeting - PDS Biotechnology ( NASDAQ:PDSB ) 10/30/2025 12:00:00 PM
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer 10/29/2025 12:37:00 PM
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer - PDS Biotechnology ( NASDAQ:PDSB ) 10/29/2025 12:37:00 PM
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression ( CPS 1-19 ) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population 9/18/2025 12:45:00 PM
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer 8/25/2025 12:30:00 PM
PDSB Loss Improves as Costs Drop 8/13/2025 11:21:00 AM
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results - PDS Biotechnology ( NASDAQ:PDSB ) 8/6/2025 12:00:00 PM

Financial Details for PDSB

Company Overview
Ticker PDSB
Company Name PDS Biotechnology Corporation
Country USA
Description PDS Biotechnology Corporation (PDSB), headquartered in Florham Park, New Jersey, is a clinical-stage biopharmaceutical company pioneering innovative cancer immunotherapies through its proprietary Versamune® platform. The company is focused on developing multifunctional therapies that significantly enhance the immune response against cancer, with its lead candidate, PDS0101, undergoing clinical trials for HPV-related cancers. PDSB's commitment to efficacy and safety addresses critical unmet medical needs in oncology, positioning it strategically within the biopharmaceutical sector to potentially revolutionize cancer treatment.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/12/2025

Stock Price History
Last Day Price 0.96
Price 4 Years Ago 8.10
Last Day Price Updated 11/13/2025 2:58:23 PM EST
Last Day Volume 1,460,730
Average Daily Volume 976,032
52-Week High 2.46
52-Week Low 0.85
Last Price to 52 Week Low 12.94%

Valuation Measures
Trailing PE N/A
Industry PE 42.64
Sector PE 87.16
5-Year Average PE -5.90
Free Cash Flow Ratio 1.41
Industry Free Cash Flow Ratio 12.80
Sector Free Cash Flow Ratio 27.84
Current Ratio Most Recent Quarter 2.76
Total Cash Per Share 0.68
Book Value Per Share Most Recent Quarter 0.34
Price to Book Ratio 3.12
Industry Price to Book Ratio 33.42
Sector Price to Book Ratio 33.38
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 25.55
Sector Price to Sales Ratio Twelve Trailing Months 14.03
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 47,025,500
Market Capitalization 45,144,480
Institutional Ownership 16.43%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 12.42%
Reported EPS 12 Trailing Months -0.91
Reported EPS Past Year -0.42
Reported EPS Prior Year -1.03
Net Income Twelve Trailing Months -36,602,208
Net Income Past Year -37,610,000
Net Income Prior Year -42,942,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 31,873,495
Total Cash Past Year 41,689,591
Total Cash Prior Year 56,560,517
Net Cash Position Most Recent Quarter 18,929,839
Net Cash Position Past Year 32,484,836
Long Term Debt Past Year 9,204,755
Long Term Debt Prior Year 19,506,183
Total Debt Most Recent Quarter 12,943,656
Equity to Debt Ratio Past Year 0.67
Equity to Debt Ratio Most Recent Quarter 0.55
Total Stockholder Equity Past Year 19,004,848
Total Stockholder Equity Prior Year 26,130,947
Total Stockholder Equity Most Recent Quarter 15,959,784

Free Cash Flow
Free Cash Flow Twelve Trailing Months -34,367,125
Free Cash Flow Per Share Twelve Trailing Months -0.73
Free Cash Flow Past Year -35,059,000
Free Cash Flow Prior Year -33,636,004

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.03
MACD Signal -0.04
20-Day Bollinger Lower Band 0.81
20-Day Bollinger Middle Band 1.15
20-Day Bollinger Upper Band 1.49
Beta 1.08
RSI 56.07
50-Day SMA 1.38
150-Day SMA 4.00
200-Day SMA 4.34

System
Modified 11/13/2025 6:29:39 AM EST